Department of Respiratory Diseases, Centre Hospitalier et Universitaire (CHU) Montpellier, and Institut National de la Santé et de la Recherche Médicale (INSERM) U1046, Université Montpellier 1, Université Montpellier 2, Montpellier, France.
Department of Respiratory Diseases, Centre Hospitalier et Universitaire (CHU) Montpellier, and Institut National de la Santé et de la Recherche Médicale (INSERM) U1046, Université Montpellier 1, Université Montpellier 2, Montpellier, France.
Chest. 2012 Jun;141(6):1504-1511. doi: 10.1378/chest.11-0232. Epub 2011 Dec 1.
The clinical manifestations of bronchial remodeling in asthma and the potential impact of this process on lung function remain unclear. We aimed to determine whether the presence of pathologic features of airway remodeling in patients with asthma was associated with steroid responsiveness in the short term.
Sixty-three consecutive patients with severe asthma with chronic airflow impairment (post-bronchodilator FEV(1) < 80% predicted values) were recruited, clinically characterized, and had an initial bronchoscopy where endobronchial biopsy and BAL were performed. BAL cellular content was reported and reticular basement membrane (RBM) thickness was measured by validated repeated measures. Patients were then treated with 1 mg/kg/d of methyl prednisone, directly administered IV, for 10 days. A threshold of 15% FEV(1) improvement was used to discriminate responsive (group 1) and refractory patients (group 2).
Thirty-eight patients had a steroid responsiveness > 15% (group 1) and a thinner RBM at the biopsy level (5.78 ± 2.0 μm vs 7.60 ± 2.2 μm; P = .001) compared with nonsteroid responsive group 2 patients as defined. The best predictors for being unresponsive were no long-term treatment with oral steroids and increased RBM thickness. The associated receiver operating characteristic curve indicated that RBM thickness could predict steroid responsiveness below 15% with an area under the curve of 0.747 (P = .0002) at a threshold of 7 μm.
Features of airway remodeling are associated with limited short-term steroid responsiveness in severe asthma.
哮喘支气管重塑的临床表现以及该过程对肺功能的潜在影响尚不清楚。我们旨在确定哮喘患者气道重塑的病理特征是否与短期类固醇反应性相关。
连续招募了 63 例慢性气流受限(支气管扩张剂后 FEV1 < 80%预计值)的严重哮喘患者,对其进行临床特征描述,并进行初始支气管镜检查,进行支气管内膜活检和 BAL。报告 BAL 细胞含量,并通过验证的重复测量法测量网状基底膜(RBM)厚度。然后,患者接受 1mg/kg/d 的甲基泼尼松龙,直接静脉内给药,持续 10 天。以 15%的 FEV1 改善作为区分有反应(第 1 组)和无反应(第 2 组)患者的阈值。
38 例患者的 FEV1 改善率> 15%(第 1 组),且活检水平的 RBM 较薄(5.78 ± 2.0μm 比 7.60 ± 2.2μm;P =.001)。无长期口服类固醇治疗和 RBM 厚度增加是预测无反应的最佳指标。相关的接收者操作特征曲线表明,RBM 厚度可预测类固醇反应性低于 15%,曲线下面积为 0.747(P =.0002),阈值为 7μm。
气道重塑的特征与严重哮喘的短期类固醇反应性有限有关。